Leprosy (Hansen’s disease [HD]) is a chronic infectious disease caused by Mycobacterium leprae that primarily affects the skin and peripheral nerves. A number of other organs, including eyes and testicles, may be involved in the infection. HD has been known for over 2000 years and has afflicted millions of people worldwide. In recent times, most patients have been residents of underdeveloped nations. Hansen(1) discovered the etiologic agent over 130 years ago, but it is still not possible to culture this bacterium on solid medium or to propagate it in liquid medium. This has hampered investigation into the pathogenesis of leprosy and there is much about the disease process that we do not understand.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hansen, G. A., Undersøgelser angående Spedalskhedens Årsager, Nor. Mag. Lægevidensk. 3(Række) 4, 9 Heft 1–88 (1874).
Montestruc, E. and Berdonneau, R. Two new cases of leprosy in new-borns in Martinique. Bulletin de la Société de Pathologie exotique. 47: 781–783 (1954) (cited in Hastings, R.C. (ed). Leprosy, 2nd Edition, p. 39. Churchill Livingstone, Edinburgh, 1994).
National Communicable Disease Center, U.S. Department of Health Education and Welfare/Public Health Service, 1970 Leprosy surveillance. Report no. 1, January 1970.
Prasad, K. V. N. and Ali, P. M. Incubation period of leprosy. Indian J. Med. Research 55: 29–42 (1967).
Browne, S. G., The history of leprosy, in: Leprosy (R. C. Hastings, ed., First Edition), pp. 1–14, Churchill Livingstone, Edinburgh (1985).
Monot, M., Honoré, N., Garnier T., et al. On the origin of leprosy, Science 308: 1042 (2005).
Badger, L. F., Leprosy in the United States, Public Health Rep. 70: 525–535 (1955).
U.S. Department of Health and Human Services, Bureau of Primary Health Carehttp://bphc.hrsa.gov/nhdp/HISTORY_MAIN_PAGE.htm
Pfeiffer L. A., A summary of Hansen’s Disease in the United States—2004, ftp://ftp.hrsa.gov/bphc/pdf/nhdp/2004Regreport.pdf
Faget, G. P., Pogge, R. C., Johansen, F. A., et al., The Promin treatment of leprosy: A progress report, Public Health Rep. 58: 1729–1741 (1943).
Shepard, C. C., The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice, J. Exp. Med. 112: 445–454 (1960).
Skinsnes, O. K., The immunopathologic spectrum of leprosy, in: Leprosy in Theory and Practice, 2nd ed. (Cochrane, R. G. and Davey, T. F., eds.), pp. 152–182 (1964).
Kirchheimer, W. F. and Storrs, E. E., Attempts to establish the armadillo (Dasypus novencintus Linn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo, Int. J. Lepr. 39: 693–702 (1971).
WHO Study Group, Chemotherapy of leprosy for control programmes, WHO Tech. Rep. Ser. No. 675, WHO, Geneva (1982).
Cole, S. T., Eiglmeier, K., Parkhill, K., et al., Massive gene decay in the leprosy bacillus, Nature 409: 1007–1011 (2001).
World Health Organization, Global leprosy situation, 2006, Wkly. Epidem. Rec. 81: 309–316 (2006).
CDC, Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year)–United States, week ending December 30, 2006 (52nd week), MMWR 55 (52): 1396, (2007).
United States Department of Health and Human Services, Health Resources and Services Administration, Bureau of Primary Health Care, National Hansen’s Disease Programs, Epidemiological and Statistical Services, A summary of Hansen’s disease in the United States –2005ftp://ftp.hrsa.gov/bphc/pdf/nhdp/2005_Registry_Report.pdf
Ong, A. K. Y., Frankel, R. I., and Maruyama, M. H., Cluster of leprosy cases in Kona, Hawai‘i: Impact of the Compact of Free Association. Int J. Lepr. 67: 13–18 (1999).
Cho, S.-N., Cellona, R. V., Villahermosa, L. G., et al., Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy. Clin. Diagn. Lab. Immunol. 8: 138–142 (2001).
Klatser, P. R., Cho, S.-N., and Brennan, P. J., The contribution of serological tests to leprosy control, Int. J. Lepr. 64:S63–67 (1996).
de Wit, M. Y., Douglas, P. T., McFadden, J., et al., Polymerase chain reaction for detection of Mycobacterium leprae in nasal swab specimens. J. Clin. Microbiol. 31: 502–506 (1993).
van Beers, S. M., Izumi, S., Madjid, B., et al., An epidemiological study of leprosy by serology and polymerase chain reaction. Int. J. Lepr. 62: 1–9 (1994).
Williams, D. L., Gillis, T. P., Booth, R. J. et al. The use of specific DNA probe and polymerase chain reaction for the detection of Mycobacterium leprae. J. Infect. Dis. 162: 193–200 (1990).
Scollard, D. M., Gillis, T. P., and Williams, D. L. Polymerase chain reaction assay for the detection and identification of Mycobacterium leprae in patients in the United States, Am. J. Clin. Path. 109: 642–646 (1998).
Franzblau, S. G., Biswas, A. N., Jenner, P., et al., Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for in vitro screening of antileprosy drugs, Lepr. Rev. 63: 125–133 (1992).
Chan, G. P., Garcia-Ignacia, B. Y., Chavez, V. E., et al., Clinical trial of sparfloxacin for lepromatous leprosy, Antimicrob. Agents Chemother. 38: 61–65 (1994).
Williams, D. L., Scollard, D. M., and Gillis, T. P., PCR-based diagnosis of leprosy in the United States, Clin. Microbiol. Newsl. 25: 57–61 (2003).
Gillis, T. P. and Williams, D. L., Polymerase chain reaction and leprosy, Int. J. Lepr. 59: 311–316 (1991).
Shepard, C. C., and McRae, D. H., Mycobacterium leprae in mice: Minimal infectious dose, relationship between staining quality and infectivity, and effect of cortisone, J. Bacteriol. 89: 365–372 (1965).
Krieg, R. E., and Meyers, W. M., Demonstration of Mycobacterium leprae in tissues from bacteriologically negative treated lepromatous leprosy patients (Abstract), Int. J. Lepr. 47: 367 (1979).
Harris, E. B., Landry, M. T., Sanchez, R. M., et al., Viability of Mycobacterium leprae in soil, water, and degenerating armadillo tissue and its significance, Microbios Lett. 44: 73–76 (1990).
Desikan, K. B., Viability of Mycobacterium leprae outside the human body, Lepr. Rev. 48: 231–235 (1977).
Pattyn, S. R., Use of the mouse footpad in studying thermoresistance of Mycobacterium leprae, Int. J. Lepr. 33: 611–615 (1965).
Truman, R. W., and Krahenbuhl, J. L., Viable M. leprae as a research reagent, Int. J. Lepr. 69: 1–12 (2001).
Shepard, C. C., Walker, L. L., and Vanlandingham, R., Heat stability of Mycobacterium leprae immunogenicity, Infect. Immun. 22: 87–93 (1978).
Shepard, C. C., Stability of Mycobacterium leprae and temperature optimum for growth, Int. J. Lepr. 33: 541–547 (1965).
Eiglmeier, K. J., Parkhill, J., Honore, N., et al., The decaying genome of Mycobacterium leprae, Lepr. Rev. 72: 387–398 (2001).
Cole, S. T., Comparative mycobacterial genomics, Curr. Opin. Microbiol. 1: 567–571 (1998).
Adams, J. E., Pena, M. T., Gillis, T. P., et al., Expression of nine-banded armadillo (Dasypus novemcinctus) interleuin-2 in E. coli, Cytokine. 32(5): 219–225 (2005) Epub 2005 December 9
Williams, D. L., Torrero, M., Wheeler, P. R., et al., Biological implications of Mycobacterium leprae gene expression during infection, J. Mol. Microbiol. Biotechnol. 8: 58–72 (2004).
Scollard, D. M., Adams, L. B., Gillis, T. P., et al., The continuing challenges of leprosy, Clin. Microbiol. Rev. 19(2): 338–381 (2006).
Marques, M. A., Espinosa, B. J., Xavier da Silveira, E. K. et al., Continued proteomic analysis of Mycobacterium leprae subcellular fractions. Proteomics 4: 2942–2953 (2004).
World Health Organization, Progress towards eliminating leprosy as a public health problem. Wkly. Epidem. Rec. 69: 145–151 (1994).
World Health Organization, Global leprosy situation, September 1999.Wkly. Epidem. Rec. 74: 313–316 (1999).
World Health Organization, Global leprosy situation, 2004. Wkly. Epidem. Rec. 80: 118–124 (2005).
World Health Assembly, Resolution 51.15, Elimination of leprosy as a public health problem. (1990).
World Health Organization, Global leprosy situation, 2007. Wkly. Epidem. Rec. 82: 225–232 (2007).
World Health Organization Action Programme for the Elimination of Leprosy. Leprosy elimination campaigns (LEC) and Special Action Projects for the Elimination of Leprosy (SAPEL). Questions and answers. WHO, Geneva (1997).
World Health Organization, Leprosy elimination campaigns: impact on case detection, Wkly. Epidem. Rec. 78: 9–16 (2003).
World Health Organization, Leprosy situation in the world and multidrug therapy coverage, Wkly. Epidem. Rec. 67: 153–160 (1992).
World Health Organization, Progress towards the elimination of leprosy as a public health problem, Wkly. Epidem. Rec. 68: 181–186 (1993).
Baumgart, K. W., Britton, W. H., Mullins, R. J., et al., Subclinical infection with Mycobacterium leprae—A problem for leprosy control strategies, Trans. R. Soc. Trop. Med. Hyg. 87: 412–415 (1993).
Wade, H. W., and Ledowsky, V., The leprosy epidemic at Nauru; a review with data on status since 1937, Int. J. Lepr. 20: 1–29 (1952).
Leiker, D. L., Epidemiological and immunological surveys in Netherlands New Guinea, Lepr. Rev. 31: 241–259 (1960).
Noussitou, F. M., Sansarricq, H., and Walter, J., Leprosy in Children, WHO, Geneva (1976).
Girdhar, A., Mishra, B., Lavania, R. K., et al., Leprosy in infants. Report of two cases, Int. J. Lepr. 57: 472–475 (1989).
Guinto, R. S., Epidemiology of leprosy: Current views, concepts and problems, in: A Window on Leprosy (B. R. Chatterjee, ed.), pp. 36–53, Statesman Commercial Press, Calcutta (1978).
Newell, K. W., An epidemiologist’s view of leprosy, Bull. WHO 34: 827–857 (1966).
Lara, C. B. and Nolasco, J. O. Self-healing, or abortive, and residual forms of childhood leprosy and their probably significance. Int. J. Lepr. 24: 245–263 (1956).
Sehgal, V. M., Rege, V. L., and Singh, K. P., The age of onset of leprosy, Int. J. Lepr. 45: 52–55 (1977).
Pönnighaus, J. M., Fine, P. E. M., Sterne, J. A. C., et al., Incidence rates of leprosy in Karonga District, Northern Malawi; Patterns by age, sex, BCG status and classification, Int. J. Lepr. 62: 10–23 (1994).
Pfeifer, L. A., A summary of Hansen’s Disease in the United States-2003. ftp://ftp.hrsa.gov/bphc/pdf/nhdp/2003Regreport.pdf
Gray, H. H., and Dreisbach, J. A., Leprosy among foreign missionaries in northern Nigeria, Int. J. lepr. 29: 279–290 (1961).
Mathai, R., Rao, P. S. S., and Job, C. K., Risks of treating leprosy in a general hospital (Abstract), Int. J. Lepr. 47: 322 (1979).
Law A. V. S., Wisniewski R. A., Kalaupapa National Historical Park and the Legacy of Father Damien. A Pictorial History. Pacific Basin Enterprises. (1988).
Kluth, F. C., Leprosy in Texas: Risk of contracting the disease in the household, Tex. State J. Med. 52: 758–789 (1956).
Filice, G. A. and Fraser, D. W., Management of household contacts of leprosy patients, Ann. Intern. Med. 88: 538–542 (1978).
Chaudhury, S., Hazra, S. K., Saha, B., et al., An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis, Int. J. Lepr. 62: 389–394 (1994).
Badger, L. F., Epidemiology, in: Leprosy in Theory and Practice, 2nd ed. (R. G. Cochrane and T. F. Davey, eds.), pp. 69–97, John Wright, Bristol (1964).
Worth, R. M., Is it safe to treat the lepromatous patient at home? A study of home exposure to leprosy in Hong Kong, Int. J. Lepr. 36(2): 296–302(1968).
Brubaker M. L., Binford C. H., and Trautman J. R., Occurrence of leprosy in U.S. veterans after service in endemic areas abroad, Public Health Rep. 84(12): 1051–1058 (1969).
Lamfers, E. J. P., Bastiaans A. H., Mravunac M., et al., Leprosy in the acquired immunodeficiency syndrome. Ann. Intern. Med. 107: 111–112 (1987).
Kawuma, H. J. S., Bwire, R., and Adatu-Engwau, F., Leprosy and infection with the human immunodeficiency virus in Uganda: a case-control study, Int J. Lepr. 62(4): 521–526 (1994).
Frommel, D., Tekle-Haimanot, R., Verdier, M., et al., HIV infection and leprosy: a four-year survey in Ethiopia, Lancet 344: 165–166 (1994).
Van den Broek, J. Chum H. J., Swai S., et al., Association between leprosy and HIV infection in Tanzania, Int J. Lepr. 65: 203–210 (1997).
Lawn, S. D., Wood, C., and Lockwood, D. N., Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person, Clin. Infect. Dis. 36: e5–e6 (2003).
Couppié, P., Abel, S., Voinchet, H., et al., Immune reconstitution inflammatory syndrome associated with HIV and leprosy, Arch, Derm, 140: 997–1000 (2004).
Pönnighaus, J. M., Fine, P. E. M., Sterne, J. A. C., et al., Extended schooling and good housing conditions are associated with reduced risk of leprosy in rural Malawi, Int. J. Lepr. 62: 345–353 (1994).
Chakravatti, M. R., and Vogel, F., A twin study on leprosy, Topics in Human Genetics. No. 1, Thieme, Stuttgart (1973).
De Vries, R .R. P., Nijenhuis, L. E., Lai, R. F. M., et al., HLA-linked genetic control of host response to Mycobacterium leprae, Lancet 308: 1328–1330 (1976).
Marquet, S. and Schurr, E. Genetics of susceptibility to infectious diseases: tuberculosis and leprosy as examples, Drug Metab. Dispos. 29: 479–483 (2001).
van de Vosse, E., Hoeve, M. A., and Ottenhoff, T. H., Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae, Lancet Infect. Dis. 4: 739–749 (2004).
Burgner, D. and Levin, M., Genetic susceptibility to infectious diseases, Ped. Infect. Dis J. 22(1): 1–6 (2003).
van Eden, W., de Vries, R. R. P., Occasional review—HLA and leprosy: a re-evaluation, Lepr. Rev. 55: 89–104 (1984).
Serjeanston, S.W., HLA and susceptibility to leprosy, Immunol. Rev. 70: 89–112 (1983).
Todd, J. R., West, B. C., and McDonald, J. C., Human leukocyte antigen and leprosy: study in northern Louisiana and review, Rev. Infect. Dis. 12(1): 63–74 (1990).
Roy, S., Frodsham, B., Hazra, S. K., et al., Association of Vitamin D receptor genotype with leprosy type, J. Infect. Dis. 179: 187–191 (1999).
Moraes, M. O., Pacheco, A., Schonkeren, J. J. M., et al., Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy, Genes and Immunity 5(7): 592–595(2004).
Job, C. K., Chehl, S. K., and Hastings, R. C., Transmission of leprosy in nude mice through thorn pricks, Int. J. Lepr. 62: 395–398 (1994).
Bechelli, L. M., Garbojosa, P. G., Gyi, M. M., et al., Site of early skin lesions in children with leprosy, Bull. WHO 48: 107–111 (1973).
Enna, C. D., Jacobson, R. R., Trautman, J. R., et al., Leprosy in the United States, 1967–1976, Public Health Rep. 93: 468–473 (1978).
Pedley, J. C., The hypothesis of skin to skin transmission, Lepr. Rev. 48: 295–297 (1977).
Davey, T. F., and Rees, R. J. W., The nasal discharge in leprosy: Clinical and bacteriologic aspects, Lepr. Rev. 45: 121–134 (1974).
Rees, R. J. W., and McDougall, A. C., Airborne infection with Mycobacterium leprae in mice, J. Med. Microbiol. 10: 63–68 (1977).
Chehl, S., Job, C. K., and Hastings, R.C., Transmission of leprosy in nude mice. Am. J. Trop. Med. Hyg. 34: 1161–1166 (1985).
Vilani-Moreno, F. R., Arruda, M. S. P., Nogueira, M. E. S., et al., Hanseniase experimental murina: inoculação do Mycobacterium leprae via intranasal. Hansen. Int. 24: 115–120 (1999), cited in Naafs, B. Silva, E., Vilani-Moreno, F. R., et al., Factors influencing the development of leprosy: an overview, Int J. Lepr. 69: 26–33(2001).
Job, C. K., Nasal mucosa and abraded skin are the two routes of entry of Mycobacterium leprae, The Star, Carville, Louisiana, 49: 1 (1990).
Narayanan, E., Sreevatsa, Kirchheimer, W. F., et al., Transfer of leprosy bacilli from patients to mouse footpads by Aedes aegypti, Lepr. India 49: 181–186 (1977).
Walsh, G. P., Storrs, E. E., Burchfield, H. P., et al., Leprosy-like disease occurring naturally in armadillos, J. Reticuloendothel. Soc. 18: 347–351 (1975).
Job, C. K., Harris, E. B., Allen, J. L., et al., A random survey of leprosy in wild nine-banded armadillos in Louisiana, Int. J. Lepr. 54: 453–457 (1986).
Centers for Disease Control, Leprosy-like disease in wild-caught armadillos, Morbid. Mortal. Week. Rep. 25: 18,23 (1976).
Lumpkin, L. R., III, Cox, G. F., and Wolf, J. E., Jr., Leprosy in five armadillo handlers, J. Am. Acad. Dermatol. 9: 899–903 (1983).
Thomas, D. A., Mines, J. S., Thomas, D. C., et al., Armadillo exposure among Mexican-born patients with lepromatous leprosy, J. Infect. Dis. 156: 990–992 (1987).
Donham, K. J., and Leininger, J. R., Spontaneous leprosy-like disease in a chimpanzee, J. Infect. Dis. 136: 132–136 (1977).
Gormus, B. J., Wolf, R. H., Baskin, G. B., et al., A second sooty mangabey monkey with naturally acquired leprosy: First reported possible monkey-to-monkey transmission, Int. J. Lepr. 56: 61–65 (1988).
Ingrens, L. M., and Kazda, J., The epidemiological significance of the occurrence of M. leprae-like microorganisms in the environment, Int. J. Lepr. 52: 719 (1984).
Scollard, D. M. and Skinsnes, O. K. Oropharyngeal leprosy in art, history, and medicine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 87: 463–70 (1999).
Kashala, O., Marlink, R., Ilunga, M., et al., Infection with human immunodeficiency virus type 1 (HIV-1) and human T cell lymphotropic viruses among leprosy patients and contacts: correlation between HIV-1 cross-reactivity and antibodies to lipoarabinomannan. J. Infect. Dis. 169: 296–304 (1994).
Mira, M. T., Alcais, A., Nguyen, V. T., et al., Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427: 636–40 (2004).
Steinhoff, U. and Kaufmann, S. H. Specific lysis by CD8+ T cells of Schwann cells expressing Mycobacterium leprae antigens, Europ. J. Immunol. 18: 969–972 (1988).
Abel, L., Sanchez, F. O., Oberti, J., et al., Susceptibility to leprosy is linked to the human NRAMP1 gene, J. Infect. Dis. 177: 133–45 (1998).
Gruenheid, S. and Gros, P. Genetic susceptibility to intracellular infections: Nramp1, macrophage function and divalent cations transport, Curr. Opin. Microbiol. 3: 43–8 (2000).
Ottenhoff, T. H. and de Vries, R. R., HLA class II immune response and suppression genes in leprosy, Int. J. Lepr. 55: 521–34 (1987).
Siddiqui, M. R., Meisner, S., Tosh, K., et al., A major susceptibility locus for leprosy in India maps to chromosome 10p13, Nat. Genet. 27: 439–41 (2001).
Spies, T., Bresnahan, M., Bahram, S., et al., A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway, Nature 348: 744–7 (1990).
Roy, S., McGuire, W., Mascie-Taylor, C. G. N., et al., Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy, J. Infect. Dis. 176: 530–532 (1997).
Santos, A. R., Suffys, P. N., Vanderborght, P. R., et al., Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy, J. Infect. Dis. 186: 1687–91 (2002).
Krahenbuhl, J. L. and Adams, L. B. Mycobacterium leprae as an opportunistic pathogen. in: Opportunistic Intracellular Bacteria and Immunity (L. J. Paradise, ed.), pp. 75–90, Plenum Press, New York (1999).
Krutzik, S. R., Tan, B., Li, H., et al., TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells, Nat. Med. 11: 653–660 (2005).
Sieling, P. A. and Modlin, R. L., Regulation of cytokine patterns in leprosy, Annals New York Acad. Sci. 730: 42–52 (1994).
Yamamura, M., Uyemura, K., Deans, R. J., et al., Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254: 277–279 (1991).
Misra, N., Murtaza, A., Walker, B., et al., Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae, Immunology 86: 97–103 (1995).
Adams, L. B., Franzblau, S. G., Vavrin, Z., et al., L-arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J. Immunol. 147: 1642–1646 (1991).
Scollard, D. M., McCormick, G., Allen, J., Localization of Mycobacterium leprae to endothelial cells of epineural and perineural blood vessels and lymphatics, Am. J. Pathol. 154: 1611–1620 (1999).
Rambukkana, A., Yamada, H., Zanazzi, G., et al., Role of alpha 2-dystroglycan as a Schwann cell receptor for Mycobacterium leprae, Science 282: 2076–2079 (1998).
Alves, L., de Mendonca Lima, L., da Silva Maeda, E., et al., Mycobacterium leprae infection of human Schwann cells depends on selective host kinases and pathogen-modulated endocytic pathways, FEMS Microbiol. Lett. 238: 429–437 (2004).
Hagge, D., Robinson, S. O., Scollard, D., et al., A new model for studying the effects of Mycobacterium leprae on Schwann cell and neuron interactions, J. Infect. Dis. 186: 1283–1296 (2002).
Spierings, E., De Boer, T., Zulianello, L., et al., Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae, Immunol. Cell. Biol. 78: 349–355 (2000).
Hietaharju, A., Croft, R., Alam, R., et al., Chronic neuropathic pain in treated leprosy, Lancet 356: 1080–1 (2000).
Richardus, J. H., Nicholls, P. G., Croft, R. P., et al., Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up, Int. J. Epidemiol. 33: 337–43 (2004).
Khanolkar-Young, S., Rayment, N., Brickell, P. M., et al., Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions, Clin. Exp. Immunol. 99: 196–202 (1995).
Jacobs, J. M., Shetty, V. P. and Antia, N. H., Teased fibre studies in leprous neuropathy, J. Neurol. Sci. 79: 301–13 (1987).
Daniel, E., Ffythche, T. J., Sundar Rao, P. S., et al., Incidence of ocular morbidity among multibacillary leprosy patients during a 2 year course of multidrug therapy, Br J Ophthalmol. 90(5): 568–73 (2006).
Ridley, D. S. and Jopling, W. H. Classification of leprosy according to immunity – a five-group system, Int. J. Lepr. 34: 255–273 (1966).
Becx-Bleumink, M. and Berhe, D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia, Int. J. Lepr. 60: 173–84 (1992).
Kumar, B., Dogra, S., and Kaur, I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India, Int. J. Lepr. 72: 125–33 (2004).
Scollard, D. M., Smith, T., Bhoopat, L., et al., Epidemiologic characteristics of leprosy reactions, Int. J. Lepr 62: 559–567 (1994).
Ridley, D. S. and Radia, K. B. The histological course of reactions in borderline leprosy and their outcome. Int. J. Lepr 49: 383–92 (1981).
Taylor, D.D., Sullivan, S.A., Eblen, A.C., et al., Modulation of T-cell CD3-zeta chain expression during normal pregnancy, J. Reprod. Immunol. 54(1–2): 15–31(2002).
Lockwood, D. N. J. and Sinha, H. H., Pregnancy and Leprosy: A Comprehensive Literature Review, Int. J. Lepr. 67(1): 6–12(1999).
Martiniuk, F., Rao, S. D., Rea, T. H., et al., Leprosy as Immune Reconstitution Syndrome In HIV-positive Persons. [letter] Emerg. Infect. Dis. [serial on the Internet]. 13 (9) Sep 2007. Available from http://www.cdc.gov/eid/content/13/9/1438.htm
Trindade, M. A., Valente, N. Y., Manini, M. I., et al., Two patients coinfected with Mycobacterium leprae and human immunodeficiency virus type 1 and naïve for antiretroviral therapy who exhibited type 1 leprosy reactions mimicking the immune reconstitution inflammatory syndrome, J. Clin. Micro. 44(12): 4626–4628 (2006) Epub 2006 October 4.
Ustianowski, A. P., Lawn, S. D., and Lockwood, D. N. J. Interactions between HIV infection and leprosy: a paradox, Lancet Infect. Dis. 6: 350–360 (2006).
Scollard, D., Joyce, M. P., and Gillis, T. P. Development of Leprosy and Type 1 Leprosy Reactions after Treatment with Infliximab: A Report of 2 Cases, Clin. Infect. Dis. 43(2):e19–22 (2006).
Moraes, M. O, Sarno, E. N., Almeida, A. S., et al., Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL), Scand. J. Immunol. 50: 541–549 (1999).
Frankel, R. I., Mita, R. T., Kim, R., et al., Resolution of Type 1 reaction in multibacillary Hansen’s disease as a result of treatment with cyclosporine, Int. J. Lepr. 60: 8–12 (1992).
Wemambu, S. N., Turk, J. L., Waters, M. F., et al., Erythema nodosum leprosum: a clinical manifestation of the Arthus phenomenon, Lancet 2: 933–5 (1969).
Sampaio, E. P., Moreira, A. L., Sarno, E. N., et al., Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients, J. Exp. Med. 175: 1729–1737 (1992).
Teo, S. K., Resztak, K. E., Scheffler, M. A., et al., Thalidomide in the treatment of leprosy, Microbes. Infect. 4: 1193–202 (2002).
Lockwood, D. N. The management of erythema nodosum leprosum: current and future options, Lepr. Rev. 67: 253–9 (1996).
Scollard, D. M. and Joyce, M. P. Leprosy (Hansen’s Disease). in: Conn’s Current Therapy (Rakel & Bope, ed.), pp. 101–106, Elsevier Science (USA), St. Louis, MO (2003).
Rea, T. H., and Jerskey, R. S. Clinical and histologic variations among thirty patients with Lucio’s phenomenon and pure and primitive diffuse lepromatosis (Latapi’s lepromatosis), Int. J. Lepr 73: 169–188 (2005).
Drosos, A. A, Brennan, P. J., Elisaf, M. S., et al., Specific antigen and antibody to Mycobacterium leprae in the cryoprecipitate of a patient with Lucio phenomenon, Rheumatol. Int. 6: 93–4 (1986).
Quismorio, F. P. Jr., Rea, T., Chandor, S., et al., Lucio’s phenomenon: an immune complex deposition syndrome in lepromatous leprosy, Clin. Immunol. Immunopathol. 9: 184–93 (1978).
Shepard, C. C., Levy, L., and Faisal, P., Rapid bactericidal effect on rifampin on Mycobacterium leprae, Am. J. Trop. Med. Hyg. 21: 446–449 (1972).
Leiker, D. L. and Kamp, H. First results of treatment of leprosy with Rifadin, Lepr. Rev. 41: 25–30 (1970).
WHO Study Group, Chemotherapy of leprosy, WHO Tech. Rep. Ser. No. 847, WHO, Geneva (1994).
World Health Organization, A Guide to Leprosy Control, 2nd ed. WHO, Geneva (1988).
Faget, G. H., Pogge, R. C., Johansen, F. A., et al., The Promin treatment of leprosy. A progress report. U.S. Pub. Hlth Rep Number 48 (1943).
Browne, S. G. and Hogerzeil, L. M., “B663” in the treatment of leprosy. A preliminary report of a pilot trial. Lepr. Rev. 33: 6–10 (1962).
Shepard, C. C., Levy, L., and Faisal, P., Rapid bactericidal effect on rifampin on M. leprae, Am. J. Trop. Med. Hyg. 21: 446–449 (1972).
Freerksen, E., Rosenfeld, M., Depasquale, G., et al., The Malta Project: a country freed itself of leprosy. A 27-year progress study (1972–1999) of the first successful eradication of leprosy, Chemotherapy 47: 309–331 (2001).
Schatz, A., Bugie, E., and Waksman, S. A., Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria, Proc. Soc. Exper. Biol. Med. 55: 66–69 (1944).
Medical Research Council, Streptomycin treatment of tuberculous meningitis, Lancet. 1: 582–596 (1948).
Medical Research Council. Prevention of streptomycin resistance by combined chemotherapy: a Medical Research Council investigation, Brit. Med. J. 1: 1157–1162 (1952).
Pettit, J. H. S. and Rees, R. J. W., Sulphone resistance in leprosy. An experimental and clinical study, Lancet 19: 673–674 (1964).
WHO Study Group. Chemotherapy of leprosy for control programs. World Health Organization Technical Report Series 675
Jamet, P., Baohong, J., Marchoux Study Group. Relapse after long-term follow up of multibacillary patients treated by WHO Multidrug Regimen, Int. J. Lepr. 63: 195–201 (1995).
Gelber, R. H., Balagon, M. V. F., and Cellona, R. V. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int. J. Lepr. 72: 493–500 (2004).
7th WHO Expert Committee on Leprosy, WHO Tech. Rep. Ser. No. 874, WHO, Geneva (1998).
Ji, B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr. Rev. 69: 106–109 (1998).
Single-Lesion Multicentre Trial Group. Efficacy of single-dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Indian J. Lepr. 69: 121–129 (1997).
Revankar, C. R., Bulchand, H. O., Pai, V. V., et al. Relapse rate in paucibacillary leprosy treated with single dose. Int. J. Lepr. 69:S131 (2001).
Lockwood, D. N. J., Rifampicin/Minocycline and ofloxacin for single lesions—what is the evidence? Lepr. Rev. 68: 299–300 (1997).
Gelber, R. H., Iranmanesh, A., Murray, L., et al., Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice, Antimicrob. Agents Chemother. 36: 2544–2547 (1992).
Grosset, J. H., Ji, B., Guelpa-Lauras, C.-C., et al., Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy, Int. J. Lepr. 58: 281–295 (1990).
Gelber, R. H., Fukuda, K., Byrd, S., et al., A clinical trial of minocycline in lepromatous leprosy, Brit. Med. J. 304: 91–92 (1992).
Chan, G. B., Garcia-Ignacio, B. Y., Chavez, V. E., et al., Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob. Agents Chemother. 38: 515–517 (1994).
Pattyn, S. R. Anti-Mycobacterium leprae activity of several quinolones studied in the mouse, Int. J. Lepr. 59: 613–617 (1991).
Noordeen, S. K., Long-term effects of chemoprophylaxis among contacts of lepromatous cases. Lepr. India 49: 504–509 (1977).
Russell, D. A., Worth, R. M., Scott, G. C., et al., Experience with acedapsone (DADDS) in a therapeutic trial in New Guinea and the chemoprophylactic trial in Micronesia, Int. J. Lepr. 44: 170–176 (1976).
Cartel, J. L., Chantaeu, S., Moulia-Pelat, J. P., et al., Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the Southern Marquesas; Results after four years. Int. J. Lepr. 60: 416–420 (1992).
Dileto, C., Blanc, L., and Levy, L., Leprosy chemoprophylaxis in Micronesia, Lepr. Rev. 71:S21–25 (2000).
Tin, K., Population screening and chemoprophylaxis for household contacts of leprosy patients in the Republic of the Marshall Islands, Int. J. Lepr. 67:S26–S29 (1999).
Convit, J., Smith, P. G., Zuniga, M., et al., BCG vaccination protects against leprosy in Venezuela: A case-control study, Int. J. Lepr. 61: 185–191 (1993).
Pönnighaus, J. M., Fine, P. E. M., Sterne, J. A. C., et al., Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi, Lancet 1: 636–639 (1992).
Orege, P. A., Fine, P. E. M., Lucas, S. B., et al., Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in Western Kenya, Int. J. Lepr. 61: 542–549 (1993).
Reddi, P. P., Amin, A. G., Khandekar, P. S., et al., Molecular definition of unique species status of Mycobacterium w; a candidate leprosy vaccine strain, Int. J. Lepr. 62: 229–236 (1994).
Chiplunkar, S. V., Kudalkar, J. L., Gangal, S. G., et al., Immuno-reactivity of mycobacterial strain ICRC and Mycobacterium leprae antigens with polyclonal and monoclonal antibodies, Int. J. Lepr. 61: 421–427 (1993).
Lockwood, D. N. J. and Suneetha, S., Leprosy: too complex a disease for a simple elimination paradigm, Bull. WHO 83: 230–235 (2005).
Rao, P. N. and Pratap, D. V. S., Leprosy programme in India: at the crossroads, Int J. Lepr. 73: 211–215 (2005).
International Sequencing Consortiumhttp://www.intlgenome.org/viewDatabase.cfm (2005).
Job, C. K., Jayakumar, J., Williams, D. L., et al., Role of polymerase chain reaction in the diagnosis of early leprosy, Int. J. Lepr. 65: 461–464 (1997).
Ustianowski, A. P. and Lockwood, D. N. J. Leprosy: current diagnostic and treatment approaches, Curr. Opin. Infect. Dis. 16: 421–427 (2003).
Suggested Reading
Hastings, R. C. (ed.). Leprosy, 2nd Edition. Churchill Livingstone, Edinburgh, (1994).
Leiker, D. L. and Nunzi, E. Leprosy in the light skin. Associazione Italiana “Amici di Raoul Follereau”, Bologna,
Ridley, D. S. Pathogenesis of leprosy and related diseases, Butterworth, London, (1988).
Sabin, T. D., Swift, T. R., and Jacobson, R. R. Leprosy, pp. 1354–1379. In Peripheral Neuropathy, Third edition, Dyck, P. J. and Thomas, P. K., editors. W. B Saunders, Philadelphia, (1993).
World Health Organization, A guide to leprosy control, WHO, Geneva, (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Frankel, R.I., Scollard, D.M. (2009). Leprosy. In: Brachman, P., Abrutyn, E. (eds) Bacterial Infections of Humans. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09843-2_20
Download citation
DOI: https://doi.org/10.1007/978-0-387-09843-2_20
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-09842-5
Online ISBN: 978-0-387-09843-2
eBook Packages: MedicineMedicine (R0)